Abstract
T-prolymphocytic leukemia (T-PLL) has a very poor prognosis with conventional immunochemotherapy. Incidental reports suggest that allogeneic hematopoietic stem cell transplantation (allo-HSCT) might have a role in this disease. Therefore, the purpose of the present study was to analyze the outcome of transplants for T-PLL registered with the European Group for Blood and Marrow Transplantation database and the Royal Marsden Consortium. Eligible were 41 patients with a median age of 51 (24–71) years; median time from diagnosis to treatment was 12 months, and in complete remission (CR) (11), partial remission (PR) (12), stable or progressive disease (13) and unknown in 5 patients. A total of 13 patients (31%) received reduced-intensity conditioning. Donors were HLA-identical siblings in 21 patients, matched unrelated donors in 20 patients. With a median follow-up of surviving patients of 36 months, 3-year relapse-free survival (RFS) and OS was 19% (95% CI, 6–31%) and 21% (95% CI, 7–34%), respectively. Multivariate analysis identified TBI and a short interval between diagnosis and HSCT as factors associated with favorable RFS. Three-year non relapse mortality and relapse incidence were each 41% with the majority of relapses occurring within the first year. These data indicate that allo-HSCT may provide effective disease control in selected patients with T-PLL.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Matutes E, Brito-Babapulle V, Swansbury J, Ellis J, Morilla R, Dearden C et al. Clinical and laboratory features of 78 cases of T-prolymphocytic leukaemia. Blood 1991; 78: 3269–3274.
Brunning RD . T-prolymphocytic leukaemia. Blood 1991; 78: 3111–3113.
Catovsky D, Ralfkiaer E, Muller-Hermelink HK . T-cell prolymphocytic leukaemia. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, 2001, pp 195–196.
Catovsky D, Matutes E, Dearden C, Osuji N, Brito-Babapulle V . The WHO classification of matureT-cell leukemias. Blood 2004; 104: 2989–2990.
Herling M, Khoury JD, Washington LT, Duvic M, Keating MJ, Jones D . A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories. Blood 2004; 104: 328–335.
Nowak D, Le Toriellec E, Stern MH, Kawamata N, Akagi T, Dyer MJ et al. Molecular allelokaryotyping of T-cell prolymphocytic leukemia cells with high density single nucleotide polymorphism arrays identifies novel common genomic lesions and acquired uniparental disomy. Haematologica 2009; 94: 518–527.
Dearden CE, Matules E, Cazin B, Tjonnfjord GE, Parreira A, Nomdedeu B et al. High remission rate in T-cell prolymphocytic leukaemia with CAMPATH-1H. Blood 2001; 98: 1721–1726.
Collins RH, Pineiro LA, Agura ED, Fay JW . Treatment of T prolymphocytic leukaemia with allogeneic bone marrow transplantation. Bone Marrow Transplant 1998; 21: 627–628.
Garderet L, Bittencourt H, Kaliski A, Daniel MT, Ribaud P, Socie G et al. Treatment of T-prolymphocytic leukaemia with nonmyeloablatove allogeneic stem cell transplantation. Eur J Haematol 2001; 66: 137–139.
Murase K, Matsunaga T, Sato T, Kuribayashi K, Kogawa K, Kawano Y et al. Allogeneic bone marrow transplantation in a patient with T-prolyphocytic leukaemia with small-intestinal involvement. Int J Clin Oncol 2003; 8: 391–394.
Okamura K, Ikeda T, Shimakura Y, Yoshiba F, Kishi K, Ando K et al. Allogeneic bone marrow transplantation for chemotherapy-resistant T-prolymphocytic leukaemia. Rinsho Ketsueki 2005; 46: 527–531.
Curtin NJ, Schwarer AP . Nonmyeloablative peripheral stem cell transplant for T prolymphocytic leukaemia complicated by fulminant haemolysis and acute renal failure at engraftment secondary to minor AB0 incompatibility. Clin Lab Haematol 2005; 27: 206–208.
DeLavallade H, Faucher C, Furst S, El-Cheikh J, Vey N, Coso D et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in a patient with T-cell prolymphocytic leukaemia: graft-versus-tumor effect and long-term remission. Bone Marrow Tranplant 2006; 37: 709–710.
Krishnan B, Else M, Tjonnfjord GE, Cazin B, Carney D, Carter J et al. Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study. Br J Haematol 2010; 149: 907–910.
Kalaycio ME, Kukreja M, Woolfrey AE, Szer J, Cortem J, Maziarz RT et al. Allogeneic hematopoietic cell transplant for prolymphocytic leukemia. Biol Blood Marrow Transplant 2010; 16: 1–5.
Rieger M, Brüggemann M, Dietrich S, Hegenbart U, Hensel M, Moos M et al. T-prolymphocytic leukemia (T-PLL) is sensitive to graft-versus-leukemia effects: Evidence from minimal residual disease (MRD) kinetics. Haematologica 2009; 94 (Suppl.3): S75–S76 (abstract).
Acknowledgements
We acknowledge all collaborating EBMT Investigators and Institutions that contributed cases to this study listed in the Appendix. Moreover, we also acknowledge Investigators and Centers that were consulted and whose cases were disqualified from the analysis.
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Appendix
Appendix
Rights and permissions
About this article
Cite this article
Wiktor-Jedrzejczak, W., Dearden, C., de Wreede, L. et al. Hematopoietic stem cell transplantation in T-prolymphocytic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation and the Royal Marsden Consortium. Leukemia 26, 972–976 (2012). https://doi.org/10.1038/leu.2011.304
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2011.304
Keywords
This article is cited by
-
Advances and Perspectives in the Treatment of T-PLL
Current Hematologic Malignancy Reports (2020)
-
CCR7 as a novel therapeutic target in t-cell PROLYMPHOCYTIC leukemia
Biomarker Research (2020)
-
Post-transplant lymphoproliferative disorder presenting as T-prolymphocytic leukemia: a case report
Journal of Medical Case Reports (2019)
-
Effect of allogeneic hematopoietic cell transplantation for patients with T-prolymphocytic leukemia: a retrospective study from the Adult Lymphoma Working Group of the Japan Society for hematopoietic cell transplantation
Annals of Hematology (2019)
-
EBMT prospective observational study on allogeneic hematopoietic stem cell transplantation in T-prolymphocytic leukemia (T-PLL)
Bone Marrow Transplantation (2019)